Author

Tate Owen

Institution: Regulus Therapeutics (United States)

Observed institution: Regulus Therapeutics (United States)

ORCID: 0009-0006-3305-2423

Observed ORCID: 0009-0006-3305-2423

OpenAlex ID: A5061270196

Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease

2019 · Edmund C. Lee, Tania Valencia, et al. · Nature Communications · 199

2018 White Paper on Recent Issues in Bioanalysis: ‘A Global Bioanalytical Community Perspective on Last Decade of Incurred Samples Reanalysis (ISR)’ (Part 1 – Small Molecule Regulated Bioanalysis, Small Molecule Biomarkers, Peptides & Oligonucleotide Bioanalysis)

2018 · Jan Welink, Yuanxin Xu, et al. · Bioanalysis · 39

Polysome shift assay for direct measurement of miRNA inhibition by anti-miRNA drugs

2015 · John R. Androsavich, Daniel J. Sobczynski, et al. · Nucleic Acids Research · 17

Pharmacokinetics and Absorption, Distribution, Metabolism and Excretion of RGLS4326 in Mouse and Monkey, an Anti–miR-17 Oligonucleotide for the Treatment of Polycystic Kidney Disease

2023 · Amin Kamel, Tate Owen, et al. · Drug Metabolism and Disposition · 15

The nucleobase guanine at the 3’-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity

2025 · Tania Valencia, Laura Y. Yen, et al. · Nature Communications · 6

RGLS4326 Increases Urinary PC1 and PC2 Levels in Individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2021 · Edmund Lee, Tania M. Valencia, et al. · Journal of the American Society of Nephrology · 5

Sp257treatment With the Microrna-21 Inhibitor Rg-012 Given With and Withoutramipril Delays Renal Impairment Progression and Prolongs Survival Wheninitiated up to Chronic Kidney Disease (ckd) Stage 3 in a Mouse Model of Alportsyndrome

2016 · John Grundy, Cynthia Heinlein, et al. · Nephrology Dialysis Transplantation · 4

Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects

2026 · Tate Owen, Izaiah Cole, et al. · The Journal of Clinical Pharmacology · 2

Discovery of Next-Generation Anti-miR-17 Oligonucleotide RGLS8429 for Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2022 · Edmund Lee, Tania M. Valencia, et al. · Journal of the American Society of Nephrology

Works count: 9

Citation count: 287

H-index: 5

I10-index: 4